Abstract
Acne is the most common inflammatory skin disease. Interleukin-1 (IL-1) is at the beginning of the cytokine signaling cascade and may be involved in the pathogenesis of this disorder. It activates redox-sensitive transcription factors, which induce IL-6 and IL-8 expression. Interestingly, l-ascorbyl-2-phosphate (APS) was shown to have beneficial effects in patients with acne vulgaris. The mechanism of action of this agent remains unknown. Here, we investigated if APS attenuates IL-1β- or TNF-α-mediated IL-6 and IL-8 expression in SZ95 sebocytes, whereas TNF-α was used as control. We also explored NF-κB activation which is known to orchestrate IL-1β- and TNF-α-mediated cytokine expression in many cell types. Both IL-1β and TNF-α increased IL-6 and IL-8 mRNA expression in SZ95 sebocytes. However, only IL-1β induced IL-6 and IL-8 secretion. IL-1β but not TNF-α activated NF-κB canonical signaling as demonstrated by Iκ-Bα phosphorylation and degradation as well as by nuclear accumulation of NF-κB/p65. Concomitant treatment of SZ95 sebocytes with APS attenuated the effect of IL-1β and TNF-α on IL-6 and IL-8 gene expression as well as on IL-1β-mediated NF-κB signaling. In contrast, APS failed to reduce IL-1β-mediated IL-6 and IL-8 secretion, presumably by maintained IL-1β-mediated p38 activation, which is known to control IL-8 secretion. Our findings shed light into the impact of IL-1β on the inflammatory cytokine response and its molecular mechanisms in human sebocytes. Our data further suggest that the beneficial effect of APS in acne patients involves attenuation of NF-κB signaling but not reduction of IL-6 or IL-8 secretion.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Acne is considered the most common inflammatory skin disorder. It is estimated that about 93 % of adolescents suffer from acne vulgaris [9], the most common subtype of acne. Albeit our current therapeutic armamentarium against acne vulgaris encompasses a panel of usually very effective topical and/or systemic treatments other subtypes of acne such as acne conglobata, smokers’ acne or acne tarda can still be a therapeutic challenge.
Elucidating the key events that lead to an uncontrolled inflammatory response of the pilosebaceous unit will be crucial to optimize our current therapeutic options and to tailor new treatments against acne. Among the various proinflammatory mediators interleukin-1 (IL-1) is the most upstream player within the cytokine cascade. On the other hand, tumor necrosis factor-α (TNF-α) seems to play a minor role in acne inflammation. Nevertheless both cytokines are robust inducers of IL-6 and IL-8 gene expression [5, 25] and propagate an initial inflammatory response of the pilosebaceous unit in acne [21]. IL-1α-like bioactivity is present in the majority of open comedones [16]. Using a skin organ culture model it was further shown that IL-1α can induce follicular hyperkeratinisation [12]. Propionibacterium acnes and oxidized lipids, both implicated in the pathogenesis of acne vulgaris, are also capable of directly inducing proinflammatory cytokine production in human epidermal keratinocytes and HaCaT cells [11, 27, 31]. Recently, Kistowska et al. [18] further demonstrated that IL-1β and the active processed forms of this cytokine are abundant in inflammatory acne lesions. Interestingly, P. acnes was found to activate the inflammasome in monocytes/macrophages. A role of IL-1 in mediating inflammation of the pilosebaceous unit is finally highlighted by the successful treatment of patients with PAPA syndrome with IL-1 antagonists [4]. Of note, IL-1 is primarily secreted by monocytes/macrophages [7] and the reported impact of this cytokine on keratinocyte proliferation is not specific for acroinfundibular keratinocytes. There is currently no evidence for an increased sensitivity of acroinfundibular keratinocytes to IL-1 or increased expression of this cytokine compared to interfollicular keratinocytes [17]. Thus, induction of IL-1 in acne may be regarded as a rather non-specific response of the pilosebaceous unit which is superimposed on increased sebaceous lipogenesis linked to increased insulin-like growth factor and androgen signaling of puberty [23].
l-Ascorbyl-2-phosphate (APS) is a stable antioxidant derived from vitamin C. In previous open-label studies 5 % sodium APS lotion appeared to have anti-inflammatory effects in patients with acne vulgaris. These beneficial effects of topical APS in acne were recently confirmed in a randomized double-blind controlled trial [32]. The precise mechanism by which topical APS elicits its anti-inflammatory effects in patients with acne vulgaris remains unknown. However, APS may exert suppressive effects on expression of distinct proinflammatory cytokines, which are known to be induced in a redox-sensitive manner, i.e., by activation of canonical nuclear factor-κB (NF-κB) signaling [10]. Notably, magnesium APS has previously been shown to exert protective and anti-inflammatory effects on UVB-treated mouse skin [19, 26], Moreover, various APS salts (e.g., sodium, calcium, magnesium) at doses ranging from 0.01 to 3 % are used in cosmetics in which they function as antioxidants and possibly also as weak anti-inflammatory cosmeceuticals [8]. However, despite of the mechanistic link between oxidative stress and inflammation in general the commonly used antiacne agent benzoyl peroxide is a strong oxidant.
Given the potential role of IL-1 in the pathogenesis of acne we investigated the molecular mechanism of proinflammatory cytokine induction and signaling in human sebocytes. To this end we used the immortalized human sebaceous gland cell line SZ95 derived from facial human sebaceous glands [35]. In addition, we tested the hypothesis as to whether APS can alter the impact of IL-1 and/or TNF-α (used as a control) on canonical NF-κB signaling and proinflammatory cytokine induction in these cells.
Materials and methods
Cell culture and reagents
SZ95 sebocytes were routinely maintained in Sebomed® basal medium supplemented with 5 ng/ml human epidermal growth factor, 10 % fetal calf serum (FCS) (both from Biochrom, Berlin, Germany), 1 % l-glutamin, 1 % penicillin/streptomycin and 1 mM CaCl2 in a humidified atmosphere containing 5 % CO2 at 37 °C [35]. APS was purchased from Fluka (Taufkirchen, Germany), IL-1β from Biomol (Hamburg, Germany) and TNF-α from Immunotools (Friesoythe, Germany). Prior to stimulation with cytokines SZ95 sebocytes were deprived for 24 h in 0.1 % FCS (for all studies involving IL-1β) or 0 % FCS (for all studies with TNF-α).
Cell viability assays
SZ95 sebocytes were seeded into 96-well tissue culture plates at a density of 10,000 cells/well. The following day cells were treated with APS at indicated doses in presence of 0.1 % FCS. Cell viability was measured by the XTT kit after 48 h (Roche, Mannheim, Germany). Quintuplicates were used for all treatments. Experiments were performed independently three times.
Real-time RT-PCR
Cells were seeded into 3.5 cm Ø tissue culture dishes at a density of 2 × 105 cells per dish. Following deprivation from FCS and stimulation as indicated established protocols were used for total RNA preparation, cDNA synthesis and real-time RT-PCR [22]. In short, total RNA was prepared by the RNeasy® kit (Qiagen, Hilden, Germany) followed by DNAse I treatment cDNA synthesis using oligo-dT primers and RevertAid® M-MuLV reverse transcriptase (Fermentas Life Sciences, Hanover, MD, USA). Real-time RT-PCR was performed with Taq polymerase (Promega, Mannheim, Germany) in a total volume of 20 μl with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and a 200 nM concentration of intron-spanning primers. The primer sequences for IL-6 and IL-8 were identical as described before [22]. Primers for cyclooxygenase 2 (COX2) were sense 5′-TTGCTGGAACATGGAATTACCC-3′ and anti-sense 5′-GCATAAAGCGTTTGCG-GTACTC-3′. Reactions were carried out in duplicates in an ABI-prism 7000 sequence detector supplied with SDS 2.2 software (Applied Biosystems) using the following conditions: an initial activation step (2 min at 50 °C), a single denaturation step (15 min at 95 °C), followed by 40 cycles of 15 s at 95 °C and 60 s at 60 °C, and a final cycle of 15 s at 95 °C, 30 s at 60 °C and 15 s at 95 °C. Levels of gene expression in each sample were quantified applying the 2−ΔΔCT method with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control. GAPDH primers were identical with those reported before [20].
IL-6 and IL-8 protein analysis
Commercially available ELISAs from Ray Bio (Norcross, GA) were used to determine the amounts of IL-6 and IL-8 proteins generated by SZ95 sebocytes. Secreted levels of IL-6 and IL-8 were measured in culture supernatants of cells seeded into 3.5 cm Ø tissue culture dishes at a density of 200,000 cells per dish. All measurements were performed in duplicates according the manufacturer’s protocol. Experiments were performed independently at least three times.
Detection of prostaglandin E2
A commercially available ELISA from Cayman (Ann Arbor, MI) was used to measure prostaglandin E2 (PGE2) in cell culture supernatants of SZ95 sebocytes. Cells were stimulated as outlined above followed by duplicate measurements according to the manufacturer’s protocol.
Western immunoblotting
Serum-deprived SZ95 sebocytes were stimulated with IL-1β or TNF-α alone or in combination with APS as indicated. Cells were then either directly harvested in boiling Laemmli buffer or processed for subcellular fractionation as described before [22]. Protein concentrations in cytoplasmic and nuclear extracts were determined by the DC Protein assay kit (BioRad, Hercules, CA). Identical amounts of protein were resolved by 10 % SDS-PAGE, electrotransferred to PVDF membranes, blocked with 2 % blocking reagent (Roche, Mannheim Germany) and incubated with primary antibodies in 1 % blocking reagent overnight at 4 °C. Primary antibodies were anti-IκBα (IMGENEX, San Diego, CA), NF-κB/p65 (Biomol), anti-phospho-IκBα, anti-COX2, anti-phospho-p38 mitogen-activated protein kinase (MAPK) and anti-phospho-p42/p44 MAPK1/2 (all from Cell Signaling, Frankfurt am Main, Germany). Equal loading of protein lysates for the detection of phosphorylated p38 MAPK and phospho-p42/p44 MAPK1/2 was confirmed by stripping and reprobing the membranes with anti-p38 MAPK and anti-p42/p44 MAPK1/2 antibodies (both from Cell Signaling). In some experiments, phorbol 12-myristate 13-acetate (PMA, 50 ng/ml) was used as positive control. After washing, membranes were incubated with secondary horseradish peroxidase conjugated antibodies (Amersham-Pharmacia) in 1 % blocking reagent for 1 h at room temperature. Bound antibodies were detected using the ECL Plus chemiluminescent reagent (Amersharm-Pharmacia). Identical nuclear protein loading was confirmed by stripping the blot and reprobing it with anti-α-tubulin antibodies (Calbiochem, Schwalbach, Germany) or with an antibody against the TATA-binding protein (TBP; Abcam, Milton, UK).
Immunofluorescence analysis
SZ95 sebocytes were seeded into 8-well chamber slides at a density of 10,000 cells per well. After deprivation from FCS as outlined above and stimulation with IL-1β or TNF-α alone and in combination with APS stand cells were fixed with methanol for 30 min at −20 oC. Non-specific binding was then blocked with 5 % donkey serum for 1 h at room temperature followed by incubation for 1 h with a rabbit polyclonal antibody against NF-κB p65 (Santa Cruz Biotechnology Inc., San Diego, CA). Bound antibodies were detected with a donkey anti-rabbit antibody coupled to Texas Red (1:1500; Dianova, Hamburg, Germany). Cells were imaged and examined with a fluorescence microscope (Carl Zeiss, Oberkochen, Germany). Red fluorescence was excited using the TX3 filter (530–585 nm). Slides were finally imaged by fluorescence microscopy (Carl Zeiss, Jena, Germany).
Densitometry
Western blot images were processed for densitometric analysis using the freely available software Image J (http://rsbweb.nih.gov/ij). Mean intensities were corrected for background followed by normalization with the corresponding housekeeping gene products α-tubulin, nuclear TBP, or non-phosphorylated proteins (p38, ERK1/2) in case of phosphorylated kinases. For multiple experiments and statistical analysis mean intensities of control samples (non-treated, cytokine- or PMA-treated cells) were set as 1 and changes of intensity were calculated as fold increase or decrease from control.
Data analysis
All experiments were performed at least three times. Data were calculated as mean ± SD followed by statistical analysis using the Student’s t test for unpaired experiments. A p value of <0.05 was considered statistically significant.
Results
Effects of APS on IL-6 and IL-8 mRNA expression in SZ95 sebocytes
We first determined the effect of APS at various doses on the cell viability of sebocytes in vitro using XTT test. Incubation of SZ95 sebocytes with APS for 48 h revealed that doses of 1–1000 µg/ml were non-cytotoxic as shown in online resource 1 (Supplemental Figure 1). Next, the effect of APS on IL-6 and IL-8 mRNA expression was investigated by real-time RT-PCR after stimulation of SZ95 sebocytes with IL-1β or TNF-α. Previously, we had established that IL-1β has a time- and dose-dependent effect on the steady-state levels of both IL-6 and IL-8 mRNAs in SZ95 sebocytes [22]. Therefore, we used IL-1β at 0.1 ng/ml, which reproducibly and robustly increased the mRNA amounts of both IL-6 and IL-8 mRNA in SZ95 sebocytes, i.e., ~six- to tenfold over control (p < 0.001) (Fig. 1a, b). With regard to TNF-α only very high doses of this cytokine were capable of reproducibly increasing the mRNA levels of both IL-6 and IL-8 (online resource 1, Supplemental Figure 2a, b). Thus, for all subsequent studies TNF-α at 10 ng/ml was used. Interestingly, APS at all tested doses (1–100 µg/ml) reduced IL-1β-mediated expression of both IL-6 and IL-8 mRNA. This effect of APS appeared to be dose-dependent for IL-8 mRNA expression with an IC50 of ~100 µg/ml (Fig. 1a, b). Likewise, APS suppressed TNF-α-mediated mRNA expression of both IL-6 and IL-8 at the majority of tested doses albeit no clear-cut dose-kinetic effect could be detected (Fig. 1c, d). APS tested at various doses per se did not change the mRNA expression levels of IL-6 and IL-8 (data not shown).
Impact of IL-1β, TNF-α and APS on NF-κB signaling in SZ95 sebocytes
Since IL-6 and IL-8 expression is well known to be regulated by canonical NF-κB signaling we next wondered whether APS affects the activation of this key regulator of inflammatory cytokine responses. Upon stimulation with IL-1β or TNF-α NF-κB is activated by phosphorylation of IκBα followed by proteasomal degradation of this protein. Homo- or heterodimers of NF-κB/p65 or NF-κB/p50 translocate then to the nucleus and bind to NF-κB consensus elements, for example., in the promoters of IL-6 and IL-8. However, comparative studies on the activation of NF-κB by IL-1β and TNF-α have not been performed to the best of your knowledge in SZ95 sebocytes. Stimulation of these cells with IL-1β led to a time-dependent phosphorylation of IκBα as shown by Western immunoblotting (Fig. 2a, lower panel). This IL-1β-mediated phosphorylation was statistically significant 15 min after stimulation (mean increase: 5.94 ± 1.51-fold, n = 3, p < 0.01). In contrast, no significant phosphorylation of IκBα was detected upon stimulation of SZ95 sebocytes with TNF-α (Fig. 2b, lower panel). In accordance with these findings the protein amounts of IκBα were time dependently reduced (statistically significant at 30 min; mean decrease: 0.18 ± 0.03-fold, p < 0.0001, n = 3) after IL-1β but not after TNF-α treatment (Fig. 2a, b, upper panel). Time kinetic analyses using nuclear extracts further revealed that the amounts of NF-κB/p65 accumulated in the nucleus over time in response to IL-1β (statistically significant at 30 min; mean increase: 2.36 ± 0.33-fold, n = 3, p < 0.01) but not after TNF-α (Fig. 1c). Next, the impact of APS was assessed in SZ95 sebocytes using two NF-κB activation read-outs after stimulation with IL-1β. Nuclear translocation of NF-κB/p65 was reduced by APS as shown by immunofluorescence analysis (Fig. 2d). As shown by Western immunoblotting APS (10 µg/ml) also markedly reduced the extent of IκBα phosphorylation in cells stimulated with IL-1β (mean decrease: 0.37 ± 0.02-fold, p < 0.05, n = 4) (Fig. 2e). As expected, APS did neither alter the expression or phosphorylation of IκBα nor the immunolocalization of NF-κB/p65 in SZ95 sebocytes treated with TNF-α (data not shown).
APS does not alter IL-1β and TNF-α-mediated secretion of both IL-6 and IL-8 by SZ95 sebocytes
The findings show that APS reduces both IL-1β- and TNF-α-mediated mRNA expression of IL-6 and IL-8 and is also capable of attenuating IL-1β-mediated NF-κB activation suggested that this antioxidant may also suppress the secretion of IL-6 and IL-8 by SZ95 sebocytes. Thus, the levels of IL-6 and IL-8 were determined by ELISA after stimulation of SZ95 sebocytes with IL-1β and TNF-α alone and in presence of different concentrations of APS. Stimulation with IL-1β (0.1 ng/ml) for 24 h resulted in a significant increase in the secreted amounts of both IL-6 and IL-8 (p < 0.001) (Fig. 3a, b). However, in contrast to the corresponding mRNA levels (Fig. 1a, b) APS at doses ranging from 1 to 100 µg/ml failed to alter IL-1β-mediated secretion of both cytokines in SZ95 sebocytes compared with IL-1β alone (Fig. 3a, b). Stimulation of cells for shorter time periods, i.e., for 3 and 12 h, likewise did not disclose a modulatory effect of APS on IL-1β-mediated secretion of both cytokines. As expected, APS per se did not affect secretion of IL-6 and IL-8 as determined by stimulation of cells with one representative APS dose (10 µg/ml) (data not shown). When supernatants of SZ95 sebocytes exposed to TNF-α alone or in combination with APS were further tested we could not detect any significant changes in the amount of both IL-6 and IL-8 compared to non-treated controls (data not shown).
APS does not alter IL-1β-mediated activation of p38 MAPK in SZ95 sebocytes
Puzzled by the observation that APS attenuates IL-1β-mediated NF-κB activation (Fig. 2c–e) and NF-κB-dependent gene expression but does neither suppresses IL-6 nor IL-8 secretion we wondered as to whether this antioxidant may alter the activation of MAPKs in SZ95 sebocytes. Detailed molecular studies from others revealed that distinct members of the MAPK family, especially p38 MAPK, are crucially involved in the regulation of IL-8 secretion in the context of NF-κB-mediated IL-8 gene expression [14]. Thus, we checked the activated state of p38 MAPK in total cell lysates of SZ95 sebocytes by Western immunoblotting using phosphospecific antibodies. Treatment with IL-1β induced significant phosphorylation of p38 MAPK in SZ95 sebocytes (mean increase: 1.64 ± 0.31-fold, p < 0.05, n = 3). However, concomitant incubation with APS did not alter the extent of p38 MAPK phosphorylation (Fig. 4a). Interestingly, APS per se decreased p38 MAPK phosphorylation (mean decrease: 0.30 ± 0.28-fold, p < 0.05, n = 3). The lack of an effect of APS on IL-1β-mediated p38 MAPK phosphorylation was further observed when cells were treated with the artificial protein kinase C activator PMA (online resource 1, Supplemental Figure 3a). Here, PMA increased p38 MAPK phosphorylation without further modulation by APS. In contrast to these findings we could not detect any changes in the phosphorylated state of p42/p44 MAPK1/2/ERK1/2 (extracellular signal-regulated kinase 1/2) in SZ95 sebocytes by IL-1β compared to non-stimulated cells (Fig. 4b). Likewise PMA did not alter constitutive p42/p44 ERK1/2 phosphorylation in SZ95 sebocytes (online resource 1, Supplemental Figure 3b). Given the regulatory role of p38 MAPK on IL-8 secretion we also wondered whether phosphorylation of p38 MAPK would be modulated by TNF-α or APS in SZ95 sebocytes. Treatment with either substances (or both) interestingly reduced the phosphorylated state of this kinase (for TNF-α mean decrease: 0.47 ± 0.18-fold, p < 0.05, n = 4) (Fig. 4c). In contrast, neither TNF-α nor TNF-α plus APS had significant effects on ERK1/2 phosphorylation in SZ95 sebocytes in multiple experiments (Fig. 4d).
Impact of IL-1β, TNF-α and APS on COX2 expression and PGE2 secretion in SZ95 sebocytes
We finally investigated the effects of IL-1β, TNF-α and APS on the expression of COX2 and PGE2 in SZ95 sebocytes. PGE2 has been implicated in the pathogenesis of acne and has also been suggested to be a viable target for the treatment of this disease [28, 33, 34]. Previous studies had revealed the presence of the full enzymatic machinery for the biosynthesis of leukotriene B4 and PGE2 in sebaceous glands of acne patients and SZ95 sebocytes, respectively [2]. Albeit it was shown that arachidonic acid stimulated the biosynthesis of PGE2 in SZ95 sebocytes, the impact of IL-1β and TNF-α on COX2 expression and PGE2 secretion is unknown. As demonstrated by real-time RT-PCR both IL-1β and TNF-α had upregulating effects on the mRNA level of COX2 (p < 0.05, n = 3 for IL-1β; p < 0.05, n = 4 for TNF-α) (Fig. 5a, b). Interestingly, APS at all tested doses (1–100 µg/ml) suppressed the effect of TNF-α but not of IL-1β on COX2 mRNA expression (Fig. 5a, b). However, the modulating effects of TNF-α, IL-1β and also of APS—in case of TNF-α-mediated COX2 mRNA expression—were not associated with altered COX2 protein levels in SZ95 sebocytes (Fig. 5c). This lack of an effect of IL-1β and TNF-α on COX2 was confirmed by measuring the amounts of PGE2 in the supernatants of SZ95 sebocyte cultures. Basal secretion of PGE2 within 24 h was 73.19 ± 3.6 pg/ml per 100,000 cells. Neither IL-1β, TNF-α nor APS had any impact on the levels of PGE2. Further, different time points, i.e., stimulation with the above agents for 1, 3 and 16 h, did not have any effect on the secretion of this short-term mediator (data not shown).
Discussion
In this study we have examined the impact of two key proinflammatory cytokines, IL-1β, TNF-α, but also of the antioxidant APS on IL-6 and IL-8 expression and NF-κB signaling in the human sebaceous gland cell line SZ95. While IL-1 has been shown to be involved in inflammatory processes in human sebocytes in vivo and in vitro, TNF-α is probably not a mediator of inflammation in these cells. Our hypothesis to test APS in this context was first based on the clinical observation that APS has beneficial effects in patients with acne vulgaris [32]. Second, APS is an antioxidative vitamin C derivative. Previous studies revealed that vitamin C is capable of reducing NF-κB-dependent induction of IL-8 gene expression by TNF-α in the human histiocytoma lymphoma cell line U937 [30]. Moreover, vitamin C inhibited activation of NF-κB and NF-κB-dependent gene IL-8 expression by TNF-α in the endothelial cell line ECV304 and in primary human umbilical vascular endothelial cells [3]. Bowie and O´Neill [3] disclosed that vitamin C blocked IL-1α and TNF-α-mediated degradation and phosphorylation of IκBα due to inhibition of IκB kinase activation. However, in both of these studies it was not described if vitamin C also inhibited IL-8 protein expression or secretion. Our findings on the inhibitory effect of APS on IL-1β in SZ95 sebocytes are in accordance with the previously described effect of vitamin C in U937 and endothelial cells. Accordingly, attenuation of NF-κB signaling in SZ95 sebocytes was demonstrated by reduced phosphorylation of IκBα and reduced nuclear accumulation of NF-κB/p65 following stimulation with IL-1β. Interestingly, TNF-α, which also induces IL-8 gene expression, did not appear to affect NF-κB activation in SZ95 sebocytes as evidenced by the lack of IκBα degradation, phosphorylation and no detectable nuclear accumulation of p65. Thus, NF-κB activation in SZ95 sebocytes seems to be a specific IL-1-mediated event, indicating a major role of IL-1 in sebocyte inflammatory processes, as previously shown. Molecular studies revealed that IL-8 gene expression is extremely complex and coordinated by at least three events: (a) derepression of the gene promoter; (b) transcriptional activation of the gene by NF-κB and JUN N-terminal protein kinase pathways; and (c) stabilization of the mRNA by the p38 MAPK pathway [13]. For IL-6 gene expression activation of the transcription nuclear factor-IL-6 (NF-IL6) is also critical [1]. IL-8 protein expression and secretion was found to depend on distinct MAPK kinase kinases which can activate NF-κB, i.e., stress-activated protein kinase/jun N-terminal kinase and p38 MAP kinases [14]. Indeed, our study is limited as we have not examined the activation of stress-activated protein kinase/jun N-terminal kinase by IL-1, TNF-α or APS. With regard to p38 activation others could detect phosphorylation of this kinase after TNF-α treatment of SZ95 sebocytes within 5–10 min followed by a rapid decline to basal levels [6]. This is in contrast to our findings as we noticed even reduced p38 phosphorylation after TNF-α and/or APS after 30 min of treatment. While the reduction of p38 phosphorylation by APS may be related to the antioxidative effects of this vitamin C derivative the reason for the reduction of p38 after TNF-α is unclear but may be due to compensatory dephosphorylation after early transient phosphorylation that we may have missed by studying only the 30-min time point. Interestingly, other noticed even increased p38 phosphorylation after treatment of ECV304 cells with vitamin C [3] which may be related to higher doses of this molecule compared to our studies and cell type-specific differences. In accordance with Choi et al. [6], however, SZ95 sebocytes displayed constitutive phosphorylation of both p38 and EKR1/2 even after FCS starvation. Notably, the latter authors likewise did not find any modulation of ERK1/2 phosphorylation by TNF-α which is supported by our studies. Whether the lack of a IL-6 or IL-8 secretion after TNF-α treatment of SZ95 is related to the extent or duration of p38 phosphorylation needs to be addressed in future studies. Our observation, APS did not affect IL-1β-mediated phosphorylation of p38 MAP kinase, may explain why this agent—despite of its effect on NF-κB gene expression—failed to reduce IL-1β-mediated secretion of IL-6 and IL-8.
The finding shows that APS neither reduces IL-6 and IL-8 protein expression nor affects PGE2 secretion in SZ95 sebocytes suggests another mechanism of action of this agent in patients with acne vulgaris. Indeed, the SZ95 sebaceous gland cell line has certain limitations as being an in vitro model for acne. Moreover, the administered amounts of APS in patients with acne vulgaris are markedly higher (5 %) than the doses used in our in vitro studies. Interestingly, it was reported that the quantities of lipid peroxides caused by oxidation of sebum, NF-κB/p65 protein and IL-1α are significantly higher in comedones than those in stratum corneum [29]. Moreover, the antioxidant glutathione was recently found to be lower in the stratum corneum of patients with acne than in healthy subjects [17]. In light of these observations and the modulating effect of APS on NF-κB activation other target genes than IL-6 or IL-8 may be affected by APS at the protein level in vivo in acne patients. Thus, it will be very informative to measure lipid peroxides, glutathione, and NF-κB/p65 protein in the skin of acne patients treated with APS to further elucidate the mechanism of action of this antiacne compound. Moreover, it is possible that APS exerts its beneficial effects in acne patients via modulating activation of the mechanistic/mammalian target of rapamycin complex 1 (mTORC1) which is a master regulator of cellular metabolism. Recently, it was proposed by Melnik and Schmitz [24] that therapeutic effects of antiacne agents are mediated by activation of FoxO1 and inhibition of mTORC1. Since proinflammatory NF-κB activation inhibits tuberous sclerosis complex 1 and thereby activates mTORC1 a potential link between APS and mTORC signaling may exist.
References
Akira S, Isshiki H, Nakajima T, Kinoshita S, Nishio Y, Natsuka S, Kishimoto T (1992) Regulation of expression of the interleukin 6 gene: structure and function of the transcription factor NF-IL6. Ciba Found Symp 167:47–62
Alestas T, Ganceviciene R, Fimmel S, Müller-Decker K, Zouboulis CC (2006) Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. Mol Med 84:75–87
Bowie AG, O’Neill LA (2000) Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol 165:7180–7188
Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P (2009) Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 161:1199–1201
Chaudhary LR, Avioli LV (1996) Regulation of interleukin-8 gene expression by interleukin-1beta, osteotropic hormones and protein kinase inhibitors in normal human bone marrow stromal cells. J Biol Chem 271:16591–16592
Choi JJ, Park MY, Lee HJ, Yoon DY, Lim Y, Hyun JW, Zouboulis CC, Jin M (2011) TNF-α increases lipogenesis via JNK and PI3K/Akt pathways in SZ95 human sebocytes. J Dermatol Sci 65:179–188
Dinarello CA (1994) The interleukin-1 family: 10 years of discovery. FASEB J 8:1314–1325
Elmore AR (2005) Final report of the safety assessment of l-ascorbic acid, calcium ascorbate, magnesium ascorbate, magnesium ascorbyl phosphate, sodium ascorbate, and sodium ascorbyl phosphate as used in cosmetics. Int J Toxicol 24(Suppl 2):51–111
Ghodsi SZ, Orawa H, Zouboulis CC (2009) Prevalence, severity and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol 129:2136–2141
Gloire G, Legrand-Poels S, Piette J (2006) NF-kappaB activation by reactive oxygen species: 15 years later. Biochem Pharmacol 72:1493–1505
Graham GM, Farrar MD, Cruse-Sawyer JE, Holland KT, Ingham E (2004) Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br J Dermatol 150:421–428
Guy R, Green M, Kealey T (1996) Modeling of acne in vitro. J Invest Dermatol 106:176–182
Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M (2002) Multiple control of interleukin-8 gene expression. J Leukoc Biol 72:847–855
Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D, Malinin NL, Cooper JA, Resch K, Kracht M (1999) Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol 19:6742–6753
Ikeno H, Tochio T, Tanaka H, Nakata S (2011) Decrease in glutathione may be involved in pathogenesis of acne vulgaris. J Cosm Dermatol 10:240–244
Ingham E, Eady EA, Goodwin CE, Cove JH, Cunliffe WJ (1992) Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 98:895–901
Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ (2003) Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 121:20–27
Kistowska M, Gehrke S, Jankovic D, Kerl K, Fettelschoss A, Feldmeyer L, Fenini G, Kolios A, Navarini A, Ganceviciene R, Schauber J, Contassot E, French LE (2014) IL-1β drives inflammatory responses to propionibacterium acnes in vitro and in vivo. J Invest Dermatol 134:677–685
Kobayashi S, Takehana M, Itoh S, Ogata E (1996) Protective effect of magnesium-l-ascorbyl-2 phosphate against skin damage induced by UVB irradiation. Photochem Photobiol 64:224–228
Kokot A, Metze D, Mouchet N, Galibert MD, Schiller M, Luger TA, Böhm M (2009) Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology 150:3197–3206
Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, Chen W, Nagy I, Picardo M, Suh DH, Ganceviciene R, Schagen S, Tsatsou F, Zouboulis CC (2009) New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 18:821–832
Mastrofrancesco A, Kokot A, Eberle A, Gibbons NC, Schallreuter KU, Strozyk E, Picardo M, Zouboulis CC, Luger TA, Böhm M (2010) KdPT, a tripeptide derivative of alpha-melanocyte-stimulating hormone, suppresses IL-1 beta-mediated cytokine expression and signaling in human sebocytes. J Immunol 185:1903–1911
Melnik BC, Zouboulis CC (2013) Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne. Exp Dermatol 22:311–315
Melnik BC, Schmitz G (2013) Are therapeutic effects of antiacne agents mediated by activation of FoxO1 and inhibition of mTORC1? Exp Dermatol 22:502–504
Miyazawa K, Mori A, Yamamoto K, Okudaira H (1998) Transcriptional roles of CCAAT/enhancer binding protein-beta, nuclear factor-kappaB, and C-promoter binding factor 1 in interleukin (IL)-1beta-induced IL-6 synthesis by human rheumatoid fibroblast-like synoviocytes. J Biol Chem 273:7620–7627
Nayama S, Takehana M, Kanke M, Itoh S, Ogata E, Kobayashi S (1996) Protective effects of sodium-l-ascorbyl-2 phosphate on the development of UVB-induced damage in cultured mouse skin. Biol Pharm Bull 22:1301–1305
Ottaviani M, Alestas T, Flori E, Mastrofrancesco A, Zouboulis CC, Picardo M (2006) Peroxidated squalene induces the production of inflammatory mediators in HaCaT keratinocytes: a possible role in acne vulgaris. J Invest Dermatol 126:2430–2437
Sato T, Shirane T, Noguchi N, Sasatsu M, Ito A (2012) Novel anti-acne actions of nadifloxacin and clindamycin that inhibit the production of sebum, prostaglandin E(2) and promatrix metalloproteinase-2 in hamster sebocytes. J Dermatol 39:774–780
Tochio T, Tanaka H, Nakata S, Ikeno Ikeno H (2009) Accumulation of lipid peroxide in the content of comedones may be involved in the progression of comedogenesis and inflammatory changes. J Cosm Dermatol 8:152–158
Vlahopoulos S, Boldogh I, Casola A, Brasier AR (1999) Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation. Blood 94:1878–1889
Vowels BR, Yang S, Leyden JJ (1995) Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun 63:3158–3165
Woolery-Lloyd H, Baumann L, Ikeno H (2010) Sodium l-ascorbyl-2-phosphate 5 % lotion for the treatment of acne vulgaris: a randomized, double-blind, controlled trial. Cosmet Dermatol 9:22–27
Zhang Q, Seltmann H, Zouboulis CC, Konger RL (2006) Involvement of PPARgamma in oxidative stress-mediated prostaglandin E(2) production in SZ95 human sebaceous gland cells. J Invest Dermatol 126:42–48
Zhang Q, Seltmann H, Zouboulis CC, Travers JB (2006) Activation of platelet-activating factor receptor in SZ95 sebocytes results in inflammatory cytokine and prostaglandin E2 production. Exp Dermatol 15:769–774
Zouboulis CC, Seltmann H, Neitzel H, Orfanos CE (1999) Establishment and characterization of an immortalized human gland cell line (SZ95). J Invest Dermatol 113:1011–1020
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Ikeno, H., Apel, M., Zouboulis, C. et al. l-Ascorbyl-2-phosphate attenuates NF-κB signaling in SZ95 sebocytes without affecting IL-6 and IL-8 secretion. Arch Dermatol Res 307, 595–605 (2015). https://doi.org/10.1007/s00403-015-1565-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-015-1565-z